Key stats
Market capitalization
802.88MAUD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.005AUD
About IMUGENE LIMITED
ISIN
AU000000IMU9
Sector
Health Technology
Industry
Biotechnology
Website
imugene.com
CEO
Leslie Chong
Headquarters
Carlton
Founded
1986
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0